Surrozen (SRZN)
(Delayed Data from NSDQ)
$8.44 USD
-0.56 (-6.22%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $8.40 -0.04 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRZN 8.44 -0.56(-6.22%)
Will SRZN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SRZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRZN
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
SRZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
Other News for SRZN
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Surrozen publishes study in 'eLife' on the proprietary SWEETS platform
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen presents preliminary results from Phase 1a study of SZN-043
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis